<DOC>
	<DOCNO>NCT01752543</DOCNO>
	<brief_summary>The purpose present study evaluate effect blockade vasopressin system central hemodynamic system heart failure ( HF ) patient physical exercise . The significance vasopressin system physical exercise unclear . If vasopressin significant regulator exercise hemodynamics HF , strategies intervene activation V1A-receptor might expect improve HF symptom possibly outcome . The potential effect central hemodynamic system evaluate Swan-Ganz catheter . Echocardiography perform rest submaximal work capacity infusion vasopressin receptor antagonist ( conivaptan ) placebo . Cardiac output measure thermodilution . The exercise test perform 50 % VO2 max hemodynamic echocardiographic measurement collect . The exercise test perform supine multistage bicycle .</brief_summary>
	<brief_title>Effects Exercise Hemodynamics Vasopressin Blockade Conivaptan Infusion Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Age &gt; 18 year Left ventricular ejection fraction ( LVEF ) &lt; 45 % baseline echocardiography . Treatment betablockers angiotensinconvertingenzyme ( ACE ) inhibitor least 1 month tolerate New York Heart Association ( NYHA ) Functional Class IIIII Given inform consent Women , yet enter menopause ( define menstrual bleed last 12 month ) , provide negative urine HCG enter study Signs symptomatic ongoing myocardial ischemia Known nonrevascularized coronary disease Presence hypovolemic hyponatremia ( PNa+ &lt; 130 mmol/l clinical sign volume depletion dehydration judge investigator ) . Hypernatraemia ( PNa+ ) &gt; 145 mmol/L Chronic obstructive pulmonary disease ( FEV1/FVC &lt; 70 % and/or 30 % &gt; FEV1 &lt; 50 % ) Supine systolic blood pressure &lt; 85 mmHg Significant orthostatic hypotension Standing blood pressure &lt; 80 mmHg blood pressure drop &gt; 20 mmHg change supine stand position Uncontrolled hypertension evaluate investigator Uncontrolled cardiac arrhythmia evaluate investigator Untreated serious hypothyroidism Adrenal insufficiency Poor echocardiographic window Inability perform exercise test Permanent atrial fibrillation atrial fluttering Planned coronary bypass surgery Moderate hepatic impairment ( ALAT/ASAT &gt; 3 UNL ) Presence diseases affect treatment conivaptan evaluation safety evaluate investigator Severely decrease kidney function ( eGFR &lt; 20 mL/min ) Serum K+ &lt; 3.5 &gt; 5.5 mmol/L Known conivaptan intolerability Corn allergy Dextrose Allergy Treatment potent CYP3Ainhibitors ( ketoconazole , itraconazole , clarithromycin , ritonavir , indinavir ) Treatment arginine vasopressin , oxytocin , desmopressin medication treatment hyponatremia ( lithium salt , urea demeclocycline ) Warfarin treatment Presence infection active bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Vasopressin</keyword>
	<keyword>Exercise capacity</keyword>
	<keyword>Conivaptan</keyword>
</DOC>